Oncolytic Virus Therapy

Note: This page is educational and reflects the state of the literature in 2025. It does not replace medical advice.

TL;DR

Oncolytic viruses (OVs) are genetically engineered (or naturally occurring) viruses that selectively replicate in cancer cells, lysing them and triggering a downstream anti-tumor immune response. The first FDA-approved OV — talimogene laherparepvec (T-VEC, HSV-1) for advanced melanoma in 2015 — proved the concept. The 2024–2025 wave is dominated by OV + immune checkpoint inhibitor combinations, systemic delivery research, and next-generation engineered platforms (vaccinia, adenovirus, reovirus, NDV, measles). Sources: [1], [2]

1. Two killing mechanisms in one drug

OVs work by two complementary mechanisms:

Direct oncolysis — the virus replicates inside cancer cells and lyses them.
Immune activation — viral and tumor antigens released into an inflammatory milieu prime systemic anti-tumor immunity, often turning a "cold" (immune-excluded) tumor "hot".

The second mechanism is increasingly seen as the more important one for durable response. This is why most modern OV development is positioned as immunotherapy, not cytolytic therapy. Sources: [1]

2. The viral platforms

Virus family	Examples in development	Notable property
HSV-1 (herpes)	T-VEC (approved), HF10, G47Δ / Delytact (conditional/time-limited approval in Japan for malignant glioma)	Large genome accommodates immune-modulator transgenes; T-VEC encodes GM-CSF
Adenovirus	DNX-2401, ONCOS-102, LOAd703	Well-characterized vector biology
Vaccinia	Pexa-Vec (JX-594) and others	Large genome, broad tropism, strong immunogenicity[2]
Reovirus	Pelareorep	Naturally tropic for Ras-pathway-active cells
Newcastle Disease Virus (NDV)	Various	Avian virus; selective replication in human tumors
Measles	Several engineered	Attenuated vaccine strain; strong oncolytic in trials
Coxsackievirus	CVA21 (CAVATAK)	Trials in melanoma and bladder
Poliovirus	PVS-RIPO (recombinant)	Glioblastoma intratumoral injection

T-VEC, the only FDA/EMA-approved OV, is delivered by intratumoral injection in advanced melanoma — and has informed the entire field on regulatory, biodistribution, and combination questions. Sources: [1]

3. Combinations — the actual story of 2024–2025

OV monotherapy responses are typically modest. The field is converging on combinations: Sources: [1], [2]

OV + immune checkpoint inhibitors (anti-PD-1, anti-CTLA-4) — converts "cold" tumors and pairs lytic immunogenic death with checkpoint release. T-VEC + ipilimumab has Phase II data in melanoma; many other combinations in trials.
OV + CAR-T or CAR-NK — virus releases antigens and reduces immunosuppression at the tumor site, potentially enabling cellular therapy in solid tumors. Sources: [1]
OV + radiotherapy — synergy from immunogenic cell death and viral replication.
OV + chemotherapy — established in some pancreatic and brain tumor protocols.
Multi-agent engineered OVs — single virus encoding GM-CSF + anti-PD-1 single-chain + cytokine, etc.

This combinational logic is why OVs increasingly belong in conversations about emerging therapies generally — see Emerging therapies.

4. Delivery — the unsolved problem

Intratumoral (IT) injection is the mainstay of approved use (T-VEC) and most clinical trials. It works for accessible tumors (skin, lymph node, soft tissue, image-guided liver, intracranial) but limits use in:

Diffuse metastatic disease (impractical to inject all sites).
Deep-seated tumors with no safe access.
Pediatric or fragile patients.

Systemic (IV) delivery is the holy grail and the most active research area. Barriers:

Neutralizing antibodies — most patients have pre-existing immunity to common viral families (especially adenovirus); even those who don't develop them after first dose.
Sequestration in liver, spleen, and lung.
Immune clearance — innate antiviral response.
Heterogeneous tumor uptake.

Strategies under investigation: cell carriers (mesenchymal stem cells, T cells), encapsulated delivery, immune-evading viruses, and pre-treatment immunosuppression. None is yet standard. Sources: [1], [2]

5. Imaging the virus — hNIS and friends

Engineered OVs often carry imaging reporters (most commonly hNIS — human sodium-iodide symporter) so investigators can image where the virus is replicating using PET/SPECT and radioactive iodide or pertechnetate. This enables real-time biodistribution in patients — a unique feature among biologics.

6. Safety profile

Local reactions at IT injection sites (pain, erythema, ulceration).
Flu-like syndrome — fever, chills, fatigue from systemic immune activation.
Viral shedding — tracked in trials; precautions for healthcare workers and household contacts.
Risk of disseminated infection in heavily immunosuppressed patients — generally a contraindication.
Rarely, autoimmune-style adverse events when combined with checkpoint inhibitors.

The safety profile is generally favorable, especially compared with systemic chemo.

7. Clinical signals beyond melanoma

Glioblastoma — DNX-2401, PVS-RIPO, G47Δ / teserpaturev (approved in Japan, 2021) — intratumoral injection during surgery; survival signals in selected patients. Sources: [3]
Pancreatic cancer — pelareorep + chemo; LOAd703 + chemo.
Sarcomas, head & neck, urothelial — multiple programs.
Liver tumors (HCC, metastases) — image-guided IT injection feasible; combinations under study.

The aggregate read is incremental progress, not a single breakthrough. The combination logic plus better delivery is where the next wave of approvals will likely come from. Sources: [1], [2]

8. What technologists can build

Treatment planning for IT injection — coregister imaging to plan delivery in 3D, especially for liver and intracranial.
Viral biodistribution analytics — quantify hNIS PET, model spread.
Manufacturing operations — like cellular therapies, OVs have chain-of-identity, lot-release, and cold-chain considerations.
Trial matching and pharmacovigilance — track shedding, AE reporting, contact precautions.
Combination optimization — predict OV + checkpoint synergy from baseline immune profiles.

9. Brazilian context

No OV is yet commercially approved by ANVISA; investigational use through clinical trials happens in selected centers.
Academic groups in São Paulo (USP, ICESP, A.C. Camargo) and southern Brazil have published preclinical and translational work.
Cell-therapy and biologic regulatory frameworks at ANVISA also cover OVs (RDC 505/2021 on advanced-therapy products applies).

References

Ma R, Li Z, Chiocca EA, Caligiuri MA, Yu J. The emerging field of oncolytic virus-based cancer immunotherapy. Trends Cancer 2023;9:122-139. PMID 36402738. https://doi.org/10.1016/j.trecan.2022.10.003
Xu L, Sun H, Lemoine NR, Xuan Y, Wang P. Oncolytic vaccinia virus and cancer immunotherapy. Front Immunol 2024;14:1324744. PMID 38283361. https://doi.org/10.3389/fimmu.2023.1324744
Asano J, Honda F, et al. Regulatory Issues: PMDA - Review of Sakigake Designation Products: Oncolytic Virus Therapy with Delytact Injection (Teserpaturev) for Malignant Glioma. Clin Pharmacol Ther. 2023. PMCID: PMC10400161.
U.S. National Cancer Institute. Oncolytic virus therapy. https://www.cancer.gov/about-cancer/treatment/research/oncolytic-virus
American Cancer Society. https://www.cancer.org/cancer.html
Cleveland Clinic. Cancer (overview). https://my.clevelandclinic.org/health/diseases/12194-cancer
A.C. Camargo Cancer Center. https://accamargo.org.br
Fundação do Câncer (Brasil). https://www.cancer.org.br/
Ministério da Saúde / BVS. ABC do câncer. https://bvsms.saude.gov.br/bvs/publicacoes/abc_do_cancer.pdf
ANVISA — Agência Nacional de Vigilância Sanitária. https://www.gov.br/anvisa/pt-br

Oncolytic Virus Therapy ​

TL;DR ​

1. Two killing mechanisms in one drug ​

2. The viral platforms ​

3. Combinations — the actual story of 2024–2025 ​

4. Delivery — the unsolved problem ​

5. Imaging the virus — hNIS and friends ​

6. Safety profile ​

7. Clinical signals beyond melanoma ​

8. What technologists can build ​

9. Brazilian context ​

See also ​

References ​